Blood Advances, 2017 Venetoclax is a BH3-mimetic small molecule drug that directly and selectively inhibits BCL-2. BCL-2 is highly expressed in many hematologic malignancies and is the predominant prosurvival protein in diseases such as chronic lymphocytic leukemia (CLL), follicular lymphoma, and mantle cell lymphoma.
openaire +3 more sources
Comparison of Venetoclax-Based Treatments for Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia: A Single-Center Real-World Experience. [PDF]
EJHaemHeyman B, Choi M, Kipps TJ.
europepmc +1 more source
Clinical research progress of menin inhibitors for acute myeloid leukemia: latest updates from the 2025 ASH Annual Meeting. [PDF]
Exp Hematol OncolMa C, Cui S, Wang J.
europepmc +1 more source
Chronic Lymphocytic Leukemia: Molecular Pathologies and Therapeutic Strategies. [PDF]
Int J Mol SciMeza K +9 more
europepmc +1 more source
Cost-effectiveness analysis of ibrutinib plus venetoclax for relapsed or refractory mantle cell lymphoma in China and the United States. [PDF]
Front Public HealthHe J, Liu X, Yang Q.
europepmc +1 more source
A phase 1/2 study of duvelisib plus venetoclax in patients with relapsed/refractory CLL/SLL or Richter transformation. [PDF]
Blood AdvCrombie JL +17 more
europepmc +1 more source
Acalabrutinib Versus Venetoclax Plus Obinutuzumab in Treatment-Naive Chronic Lymphocytic Leukemia: A Real-World Propensity Score-Matched Study. [PDF]
Cancer MedLiao PW, Ko BS, Su YC, Chao WT, Teng CJ.
europepmc +1 more source
Management of Acute Myeloid Leukemia in a Dialysis-Dependent Patient: A Case Report, Literature Review, and Therapeutic Considerations. [PDF]
CureusSapkota S +10 more
europepmc +1 more source